INmune Bio Reaches Commercial CORDStrom Manufacturing Milestone
BOCA RATON, Fla. | July 20, 2026 INmune Bio Inc. announced the successful completion of a major commercial manufacturing...
EMA
Advertisement
Novo Nordisk Secures EU Approval for Oral Wegovy
BAGSVÆRD, Denmark, July 15, 2026 Novo Nordisk has achieved a major regulatory milestone after the European Commission (EC) granted...
Aligos Completes Phase 2 B-SUPREME Enrollment
SOUTH SAN FRANCISCO, Calif., July 13, 2026 Aligos Therapeutics announced the completion of patient enrollment in both parts of...
Rhythm Publishes Phase 3 IMCIVREE Data in NEJM
BOSTON, Mass., July 8, 2026 Rhythm Pharmaceuticals announced that the New England Journal of Medicine (NEJM) has published the...
Revolution Medicines Advances Daraxonrasib Under EMA Review
REDWOOD CITY, Calif., July 7, 2026 Revolution Medicines has announced a major regulatory milestone as the European Medicines Agency...
Advertisements
Can-Fite Completes Phase 3 Psoriasis Trial Enrollment
RAMAT GAN, Israel, July 6, 2026 Can-Fite BioPharma announced the completion of enrollment of the first 247 patients in...
Sanofi Nexviazyme Delivers Positive Phase 3 Pompe Trial Results
PARIS, June 30, 2026 Sanofi has announced that its enzyme replacement therapy Nexviazyme® (avalglucosidase alfa) successfully met all primary...
Zambon Hopledo® Wins CHMP Backing for Parkinson’s Disease
BRESSO, Milan, Italy, June 29, 2026 Zambon has announced that the Committee for Medicinal Products for Human Use (CHMP)...
Roche Enspryng Gains FDA Priority Review for TED Treatment
BASEL, Switzerland, June 30, 2026 Roche has announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
AbbVie RINVOQ® Moves Closer to EU Approval for Alopecia Areata
NORTH CHICAGO, Ill., June 29, 2026 AbbVie has announced that the European Medicines Agency’s Committee for Medicinal Products for...
Advertisement
